Connection of Mir-185 and Mir-320A Expression Levels With Response to Interferon-Beta in Multiple Sclerosis Patients Publisher Pubmed



Mousavi SR^{1, 2} ; Tahmasebivand M² ; Khorrami M³ ; Ayromlou H⁴ ; Khalili SK² ; Khorvash F⁵ ; Rikhtegar R⁶ ; Khademi B² ; Bahmanpour Z² ; Emamalizadeh B²
Source: Multiple Sclerosis and Related Disorders Published:2020

Abstract

Background: Multiple sclerosis (MS) is an inflammatory autoimmune disease characterized by neurodegeneration in the CNS. Interferon-beta (IFN-β) is an FDA-approved drug used as the first-line treatment for relapse-remitting multiple sclerosis (RRMS). The exact mechanism of IFN-β during the treatment of RRMS still remains unknown. Recently, many studies have shifted towards the role of miRNAs in the treatment of MS patients. Methods: Herein, the expression level of miR-185–5p and miR-320a has been evaluated in order to candidate them as novel biomarkers for monitoring the response to IFN-β therapy. For this purpose, one-hundred whole blood samples from patients with RRMS were collected, consisting of 50 responders and 50 non-responders to IFN-β therapy. To predict the possible molecular mechanisms of IFN-β and highlight the role of these miRNAs, in silico analysis was applied to enrich the signaling pathways which may be involved based on the target genes of miR-185–5p and miR-320a. Results: It is identified that the differentially expressed miR-185–5p was statistically significant between the two treated groups with IFN-β. Furthermore, MAPK signaling pathway was suggested as the main non-canonical pathway involved in IFN-β therapy. Conclusion: miR-185–5p could be considered as a novel biomarker for monitoring the response to IFN-β therapy. © 2020 Elsevier B.V.